Alnylam acquires Merck’s RNAi assets and IP

13-01-2014

Biopharmaceutical company Alnylam has paid Merck $175 million for its subsidiary Sirna Therapeutics, a firm specialising in RNA interference (RNAi) therapeutics.


Alnylam, merck, rnai, sirna therapeutics,

LSIPR